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ABSTRACT
Objective: To quantify and draw inferences on the
clinical effectiveness of platelet-rich therapy in the
management of patients with a typical osteoporotic
fracture of the hip.
Design: Single centre, parallel group, participant-
blinded, randomised controlled trial.
Setting: UK Major Trauma Centre.
Participants: 200 of 315 eligible patients aged
65 years and over with any type of intracapsular
fracture of the proximal femur. Patients were excluded
if their fracture precluded internal fixation.
Interventions: Participants underwent internal fixation
of the fracture with cannulated screws and were
randomly allocated to receive an injection of platelet-
rich plasma into the fracture site or not.
Main outcome measures: Failure of fixation within
12 months, defined as any revision surgery.
Results: Primary outcome data were available for 82
of 101 and 78 of 99 participants allocated to test and
control groups, respectively; the remainder died prior
to final follow-up. There was an absolute risk
reduction of 5.6% (95% CI −10.6% to 21.8%)
favouring treatment with platelet-rich therapy (χ2 test,
p=0.569). An adjusted effect estimate from a logistic
regression model was similar (OR=0.71, 95% CI 0.36
to 1.40, z test; p=0.325). There were no significant
differences in any of the secondary outcome
measures excepting length of stay favouring treatment
with platelet-rich therapy (median difference 8 days,
Mann-Whitney U test; p=0.03). The number and
distribution of adverse events were similar. Estimated
cumulative incidence functions for the competing
events of death and revision demonstrated no
evidence of a significant treatment effect (HR 0.895,
95% CI 0.533 to 1.504; p=0.680 in favour of platelet-
rich therapy).
Conclusions: No evidence of a difference in the risk
of revision surgery within 1 year in participants
treated with platelet-rich therapy compared with those
not treated. However, we cannot definitively exclude a
clinically meaningful difference.




Platelet-rich therapies are autologous blood
products with a greater concentration of pla-
telets than physiological whole blood.1 These
preparations have been used since the early
1990s to promote bone and soft tissue
healing.1 Promising preliminary studies have
led to the use of platelet-rich therapy in
sports medicine, rheumatology and ortho-
paedic surgery with the aim of promoting
and enhancing soft tissue and bone healing.2
Platelet-rich therapies can be produced at
the bedside by either centrifugation or filter-
ing of autologous whole blood mixed with
an anticoagulant. Both these processes
produce a plasma fraction that has a supra-
physiological concentration of platelets.
Platelets have long been identified as the
main regulators of the inflammatory phase
of tissue repair.3 This same mechanism may
also influence the proliferation and differen-
tiation phases of healing tissues.3 Hence,
ARTICLE SUMMARY
Article focus
▪ To explore the difference in the risk of fixation
failure at 1 year after index fracture between
patients treated with platelet-rich therapy and
those not as an adjunct to internal fixation of an
intracapsular fracture of the proximal femur.
Key messages
▪ No evidence of a difference in the risk of revision
surgery within 1 year in participants treated with
platelet-rich therapy compared with those not
treated.
▪ A clinically meaningful difference cannot be
definitively excluded.
Strengths and limitations of this study
▪ Pragmatic trial.
▪ Includes participants with chronic cognitive
impairment.
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platelet-rich therapy has been used in an attempt to
optimise healing by delivering supraphysiological levels
of platelet-derived growth factors to the site of injury.4
At present, good-quality evidence to support the use
of platelet-rich therapy in the clinical setting remains
sparse. The National Institute of Health and Clinical
Excellence (NICE) has advised that its use should be
restricted to research settings.5 One exciting area of
research is the use of platelet-rich therapy to enhance
healing in osteoporotic fractures.6
Intracapsular fractures of the proximal femur are a
good example. Failure of internal fixation for these hip
fractures is common, with up to 35% of displaced frac-
tures requiring revision surgery.7–9 Therefore, any
adjunct that can accelerate fracture healing and reduce
the rate of failure of fixation has the potential to change
patient care.
We conducted a randomised controlled trial to quan-
tify and draw inferences on the clinical effectiveness of
platelet-rich therapy in the management of patients with
a typical osteoporotic fracture of the hip. Specifically, we
sought to explore the difference in the risk of fixation
failure at 1 year after index fracture between patients
treated with platelet-rich therapy and those not as an
adjunct to internal fixation of an intracapsular fracture
of the proximal femur.
METHODS
This study was a single centre, parallel group,
participant-blinded, randomised standard-of-care con-
trolled trial with a 1:1 allocation to main treatment
groups. Full details of the protocol have been published
elsewhere.10 The trial was given ethical approval on 6
July 2009 by the Coventry Research Ethics Committee
(09/H1210/22).
Participants
All patients aged 65 years and above with an intracapsular
hip fracture were eligible, including those with cognitive
impairment. Patients were excluded if they were managed
non-operatively, presented late following their injury, had
serious injuries to either lower limb that interfered with
rehabilitation of the hip fracture, or had extant local
disease precluding fixation, for example, local tumour
deposit and symptomatic ipsilateral hip osteoarthrosis.
Recruitment and allocation of participants
Participants were recruited between September 2009 and
April 2011 from the acute trauma admissions to University
Hospitals Coventry and Warwickshire National Health
Service (NHS) Trust, Coventry, UK. This is a major trauma
centre that serves a population of two million people.
Approximately 650 patients per year with a fracture of the
proximal femur are treated in the centre.11 Participants
with capacity gave written consent; for those who lacked
capacity, written consent was given by a consultee in
accordance with the Mental Capacity Act 2005.
Participants were randomly allocated to one of two
groups: standard-of-care fixation or standard-of-care fix-
ation and platelet-rich therapy injection. Treatment allo-
cation was determined using a computer generated,
randomised number sequence administrated by an inde-
pendent clinical trials unit via a secure online pro-
gramme. The randomisation code was stratified by
displacement of the fracture12 and split into unequal
block sizes. Stratification ensured that those fractures
which were minimally displaced that are associated with
a very substantially improved outcome, were distributed
evenly between the groups. The code was only broken at
the end of the trial once the trial statistician had locked
and analysed the dataset.
Allocation to the treatment group took place intrao-
peratively, only after the operating surgeon confirmed a
successful reduction of the fracture. Those patients in
whom a reduction could not be achieved underwent hip
arthroplasty, which reflects standard clinical practice.
Interventions
All participants underwent closed reduction of their
fracture, where the leg was manipulated until the bones
were ‘reduced’ back into their normal anatomical pos-
ition. The lower limb was supported on a fracture table.
Internal fixation of the fracture was achieved through a
standard lateral approach with perioperative antibiotic
cover in accordance with hospital protocol.
Postoperative care was the same for both groups of
patients with early active mobilisation and immediate
full weight bearing with a standardised physiotherapy
rehabilitation regime. All participants received routine
prophylaxis against deep vein thrombosis.
Standard-of-care fixation was with two or three parallel
cannulated screws. The number and exact configuration
was left to the discretion of the operating surgeon to
ensure that the results could be easily generalised. For
those participants allocated to platelet-rich therapy, each
screw was advanced up to but not beyond the fracture
such that no compression was achieved before the
platelet-rich plasma was injected. The guidewire of one
screw was then removed and 3 mL of platelet-rich plasma,
harvested in accordance with the manufacturer’s recom-
mendations (GenesisCS Component Concentrating
System, EmCyte Corporation, Fort Myers, Florida, USA),
was injected without an activator through the cannulated
screw directly into the fracture site under image intensi-
fier guidance. This preparation is a Mishra et al’s13 type
1A platelet-rich plasma, whose details of bioactivity are
available elsewhere.14 15 The guidewire was immediately
replaced and the screws advanced across the fracture site.
No attempt was made to blind the operating surgeon.
Outcome measurements
Primary
▸ The proportion of participants undergoing reopera-
tion for failure of fixation within 1 year of sustaining
the fracture.
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Secondary
▸ Radiographic non-union at 1 year. Non-union was
defined as “failure of the fracture to show signs of
bony union on the anteroposterior or lateral radio-
graph 1 year after surgery.”8
▸ Radiographic evidence of avascular necrosis at 1 year.
▸ The EuroQoL 5 Dimensions Index (EQ-5D), York A1
value set16 at 6, 12 and 52 weeks.




Very few data were available to estimate the possible size
of a treatment effect of platelet-rich therapy.17 18 The
minimum clinically important treatment effect of
platelet-rich therapy was agreed in discussion with
several expert orthopaedic trauma surgeons. Although
the figures varied by surgeon, all agreed that an absolute
risk reduction (ARR) of between 15% and 25% in fix-
ation failure would be clinically important. The overall
rate of fixation failure of all intracapsular fractures of
the femur is reported to be between 25% and 35%.7–9
Sample sizes were determined using the PS power and
sample size software.19 Selecting a power of 90%, and
the most plausible estimate of fixation failure rate (30%)
and an intermediate value for the minimum clinically
important ARR of 20% gives a treatment group size of
82. Adding 20% on to the total trial sample size estimate
to account for expected patient mortality gives a recruit-
ment target of 200 participants that should provide a
good margin for unanticipated recruitment problems
and loss to follow-up.
Statistical methods
The primary outcome measure, the proportion of
patients requiring reoperation for failure of fixation
(revision) within 1 year of sustaining the fracture, was
compared between treatment groups (fixation and fix-
ation plus platelet-rich therapy) using a χ2 test, where
data from participants were analysed by treatment alloca-
tion. Treatments were considered to differ significantly if
p values were less than 0.05. The primary analysis was an
available case analysis where deaths without revision
were excluded from the analysis. If mortality differed
between the treatment groups, this had the potential to
bias the effect estimate, so additional post hoc analyses
were undertaken with deaths imputed as both revisions
and non-revisions to assess the sensitivity of the primary
analysis to the decisions regarding handling of the
missing data.
Fisher’s exact test was used to assess the significance of
observed differences for the secondary proportional
outcome measures. For continuous outcomes, which
were approximately normally distributed, mean differ-
ences (MDs) were tested using a two-tailed t test; for
non-parametric data (length of stay), differences were
tested with the Mann-Whitney U test. A planned
subsidiary analysis used a multiple linear regression
model to investigate the relationship between each parti-
cipant’s EQ-5D score at 1 year postoperatively and the
treatment group, after appropriate adjustment for age,
sex and fracture displacement for each participant. The
incidences of adverse events were reported for each
treatment group stratified by the type of event. Planned
subgroup analyses were undertaken only for prespecified
subgroups. Explanatory variables of sex, fracture dis-
placement, dementia and age were entered into a logis-
tic regression model with associated interaction terms
with the treatment arm for each.
In addition to the primary analysis comparing risks of
revision between groups, the Data Monitoring
Committee recommended that a post hoc time-to-event
analysis was also undertaken to assess temporal differ-
ences in revision post operation. In this setting, where
failure of the fixation was the event of interest, death
was regarded as a competing risk. In the presence of
competing risks, the standard cause-specific Cox propor-
tional hazards model is not appropriate as it treats the
competing risk (death) as a censored observation.
Therefore, the approach adopted here was the propor-
tional hazards model proposed by Fine and Gray,20
based on direct regression modelling of covariates on
the cumulative incidence function (CIF). CIF, the pro-
portion of trial participants at time t who had event j
(death or revision), was used to compare treatments,
and the R software21 package cmprsk22 was used to




A summary of the flow of participants through the study
is at figure 1. Of the 388 patients admitted with an intra-
capsular hip fracture during the recruitment period,
52% underwent trial treatments, which represented 83%
of all eligible patients assessed. This was largely due to
recruitment only taking place during the working week.
Two hundred and eleven participants were enrolled
into the study, of whom 200 were randomly allocated to
treatments. Ninety-nine participants were allocated to
the control group, of whom 76 completed the trial
protocol; 101 were allocated to the test group, of whom
81 completed the protocol. In the latter group, there
were three protocol violations leading to three cross-
overs. Of the 43 participants who died, 3 underwent revi-
sion surgery prior to death, so in total 160 participants
were available for the primary analysis. The numbers of
participants unavailable at each of the four time points
for the EQ-5D score are reported in the trial flow
diagram (figure 1). Similar proportions of other second-
ary outcomes were unavailable at different follow-up
time points due to death, coexisting chronic confusional
states at the time of recruitment, new onset comorbid-
ities and participant withdrawals.
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The baseline characteristics of the trial participants
are described in table 1. There were no apparently sub-
stantial between-group differences for any of the
recorded baseline characteristics.
Treatments
Both the test and control treatments were successfully
delivered as described previously, under the supervision
of 18 consultant trauma surgeons and performed by a
total of 21 specialist trainees.
Outcomes and estimation
Table 2 shows the counts and estimated risks of revision
surgery by treatment group. There was an ARR of 5.6%
(95% CI −10.6% to 21.8%) in favour of platelet-rich
therapy (χ2 test, p=0.569).
Deaths were also approximately balanced between
treatment groups (control n=23 and test n=20).
Imputing all the deaths as ‘revisions’ increased the
overall estimates of revision risks, but due to the balance
across groups, it had little impact on effect estimates
(control risk 52.5%; ARR in favour of platelet-rich
therapy 6%, 95% CI −8.8% to 20.8%; χ2 test p=0.480).
Similarly, an equivalent analysis recoding deaths as ‘non-
revisions’ did not modify the conclusions of the primary
analysis (control risk 31.3%; ARR in favour of
platelet-rich therapy 3.6%, 95% CI −10.0% to 17.2%, χ2
test; p=0.688).
Figure 1 Flow diagram of the Consolidated Standards of Reporting Trials (CONSORT). Notes: (a) Two participants underwent
revision prior to death, (b) 1 participant underwent revision prior to death, (c) 31 participants unavailable at baseline and (d) 35
participants unavailable at baseline.
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Logistic regression analysis, with a binary response
variable (1=revised and 0=unrevised), was used to assess
the effect of treatment group allocation on revision after
adjustment for sex, fracture displacement, dementia and
age. This model gave an adjusted estimated OR of 0.71
(95% CI 0.36 to 1.40), which was marginally smaller
than the unadjusted OR of 0.79 from table 2, and pro-
vided no evidence for a significant treatment effect
(z test from logistic regression, p=0.325). In addition to
the planned variables used for the adjusted analysis,
other baseline variables (eg, diabetes) were also entered
into the regression model, but proved not to be signifi-
cant. Interaction terms were added to the model to test
for prespecified subgroup effects; that is, additional
terms were included in the model that tested to see if
the treatment effect was changed (moderated) by frac-
ture displacement, dementia or age group. Appropriate
interaction terms were added individually to the base
model to give three separate analyses; none of the inter-
action terms significantly improved the model fit, provid-
ing no evidence for substantial subgroup effects.
There was no significant difference in the unadjusted
mean EQ-5D score at 1 year between the control and
treatment groups (mean control group EQ-5D=0.588,
MD=0.018 in favour of the control group, t test;
p=0.799). After adjusting for age, sex and fracture dis-
placement, this was maintained. A summary of the other
secondary outcomes is presented in table 3. There was
no significant difference between treatment groups in
any of the measures excepting length of stay. The
number and distribution of complications were similar
in both treatment groups (table 4).
Estimated CIF curves, the probability that the event of
interest occurs before a given time, are shown for death
and revision as competing events for each treatment
group in figure 2. Estimates of HR for the competing
risks regression model are reported in table 5. The esti-
mates indicated an increased risk of revision surgery for
participants with a pre-existing diagnosis of osteoporosis
and a significantly lower risk for participants with min-
imally displaced fractures or dementia. There was no evi-
dence for a significant treatment effect (HR 0.895, 95%
CI 0.533 to 1.504; p=0.680 in favour of platelet-rich
therapy). An analogous time-to-event analysis using the
more conventional Cox proportional hazards model
gave very similar results (HR 0.819, 95% CI 0.489 to
1.372; p=0.449 in favour of platelet-rich therapy).
DISCUSSION
Principal findings
This trial has found no evidence of a difference in the
risk of revision surgery between participants receiving
platelet-rich therapy and those not as an adjunct to
internal fixation of an intracapsular fracture of the
proximal femur. However, we have been unable to
definitively exclude a clinically important difference.
A sensitivity analysis to explore the effect of decisions
regarding the handling of the missing data and the com-
peting risks of death and revision surgery found similar
estimates of the effect size.
The majority of secondary outcomes, including
radiographic, mortality and patient-reported
health-related quality-of-life measures, demonstrated
effects that were concordant with the primary outcome.
Table 1 Baseline characteristics for each group
Characteristics
Group
Control (n=99) Test (n=101)
Age (years) 83 (7.8) 83 (8.2)
Female (%) 73 69
Minimally displaced fractures (%) 22 21
Demented (AMT <8) 31 34
Premorbid EQ-5D 0.63 (0.34) 0.69 (0.30)
Previously diagnosed CRF (%) 4.0 4.9
Previously diagnosed diabetes mellitus (%) 6.1 16
Previously diagnosed osteoporosis (%) 18 18
Currently prescribed antiplatelet drug (%) 32 27
Previously or currently prescribed systemic steroid (%) 6.1 6.9
Currently prescribed NSAID (%) 4.0 3.9
Currently smoking (%) 8.1 7.9
Time to theatre (hours) 34 (33) 30 (26)
Summary statistics: mean (SD).
AMT, abbreviated mental test score; CRF, chronic renal failure; EQ-5D, EuroQoL 5 Dimensions Index; NSAID, non-steroidal anti-inflammatory
drug.
Table 2 Revision at 12 months post index operation
Group Unrevised Revised Total Risk (%)
Control 47 31 78 39.74
Test 54 28 82 34.15
Total 101 59 160 36.88
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The length of inpatient stay was significantly shorter in
the group treated with platelet-rich therapy. We are
unable to provide a biologically plausible explanation
for this difference. There was no evidence of any sub-
group interaction effects.
Strengths and limitations of this study
This was a pragmatic trial. Although it was only con-
ducted at a single centre, a large number of surgeons
were involved in the administration of both the interven-
tions. The consequent variety in reduction and fixation
strategies probably reflects wider surgical practice in a
well-recognised cohort of patients. The corollary of this,
that the case number for any one surgeon was compara-
tively low, might have reduced the assay sensitivity of the
trial. However, each surgeon was either trained to
perform the intervention or supervised suitably.
Additionally, since each individual surgeon performed
only a small number of interventions, the impact of the
‘surgeon effect’, related to both experience and tech-
nical expertise, was likely to have been small.
The hypothesis of the trial concerned the incidence
of fixation failure. Since it is difficult to define a surro-
gate outcome of revision, surgery was chosen. It is pos-
sible that other considerations, such as patient
comorbidity, may have influenced any decision to under-
take revision surgery. However, it is unlikely that such
considerations differed between the treatment groups.
Only 80% of the available population was screened for
eligibility since the trial staff was often not available
outside the working week. This might have produced a
sampling bias. However, a review of the admission and
screening data revealed no substantial differences in the
crucial confounders of age, sex, fracture displacement
and chronic cognitive impairment between the
unscreened and recruited samples.
Some participants were being treated with antiplatelet
drugs at the time of recruitment into the trial. These par-
ticipants were not excluded since the trial was pragmatic
and there is no evidence that the mechanism of release
of the platelet-derived growth factors during platelet-rich
therapy administration are dependent on the pathways
inhibited by aspirin and other antiplatelet drugs.
Comparison with other studies
Few data exist from other similar studies with which to
compare these findings.17 Indeed, to our knowledge,
this is the first trial of this size to be conducted explor-
ing platelet-rich therapy in bone healing.2
Our modelling demonstrated that fracture displace-
ment and a pre-existing diagnosis of osteoporosis were
significant predictors of revision risk. This is consistent
Figure 2 Estimated cumulative incidence function curves
death and revision as competing events for each treatment
group.
Table 3 Between-group differences in secondary outcome measures
Outcome Treatment group Test Significance
Control (n=78) Test (n=82)
Radiographic non-union at 1 year (%) 1 2 Fisher’s exact 1.00
Radiographic avascular necrosis at 1 year (%) 1 2 Fisher’s exact 1.00
Length of index hospital stay (days) 23 (10–41) 15 (7–27) Mann-Whitney 0.03
Mortality (%) 23 20 Fisher’s exact 0.61
Proportions are expressed as percentages; summary statistics as median and IQR.
Table 4 Between-group differences in complications





Wound infection 3 1
Pulmonary embolus 2 0
Pneumonia 12 9
Urinary tract infection 6 5




Myocardial infarction 1 0
Deep vein thrombosis 2 2
Death 23 20
Events are not mutually exclusive.
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with clinical experience and previous authors’ findings.8
The cohort study reported by Parker et al8 recruited
more participants than this trial and identified risk
factors with smaller effect sizes. Interestingly, our model
found that dementia was a protective factor. It is difficult
to develop a biologically plausible explanation for this
observation. It may rather reflect the reluctance to
embark upon major revision arthroplasty surgery in this
group of particularly frail patients.
Conclusions and implications
How does our work contribute to the current debate
concerning platelet-rich therapy? Very little evidence
exists to support any routine clinical applications of
platelet-rich therapy. NICE has recommended that its
use in the treatment of tendinopathy is limited to
research settings.5 To our knowledge, this trial is the first
to explore the clinical effectiveness of platelet-rich
therapy in osteoporotic bone healing.
A new NICE guideline for the management of frac-
tures of the proximal femur suggests arthroplasty, with a
risk of revision of approximately 5%, as opposed to
internal fixation for this group of patients with displaced
fractures.23 We have been unable to definitively exclude
an important treatment effect for platelet-rich therapy,
but in the absence of an approximately 20% reduction
in the risk of revision surgery following internal fixation
with platelet-rich therapy, arthroplasty will remain the
standard of care.
Future work might investigate the effectiveness of
platelet-rich therapy in different fracture types such as
incomplete fractures or those in bone of normal density.
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